Sorafenib for ovarian cancer

Expert Opinion on Investigational Drugs

Volumn 22, Issue 8, 2013, Pages 1049-1062

  Maggiore, Umberto Leone Roberti ^a   Menada, Mario Valenzano ^a   Venturini, Pier Luigi ^a   Ferrero, Simone ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Efficacy; Ovarian cancer; Safety; Tolerability; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; PACLITAXEL; PLACEBO; SORAFENIB; TOPOTECAN;

ACNE; ALOPECIA; ANEMIA; ANOREXIA; ANUS FISSURE; ARTICLE; CANCER CHEMOTHERAPY; CONSTIPATION; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVARY CANCER; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRURITUS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; NIACINAMIDE; OVARIAN NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84880203686     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.802769     Document Type: Article

References (74)

1. Hunn J, Rodriguez GC. Ovarian cancer: Etiology, risk factors, and epidemiology. Clin Obstet Gynecol 2012;55:3-24
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology-. Ovarian Cancer. Version 1.2013. Available from: Http://www.nccn.org/professionals/physician-gls/pdf/ovarian.pdf [Accessed 2 May 2013]
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29
4. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011;121:230-8
5. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol 2006;95:161-92
6. Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:23-30
7. Wright JD, Shah M, Mathew L, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer 2009;115:4118-26
8. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248-59
9. Du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:1234-44
10. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis. Gynecol Oncol 2009;112:265-74
11. Morgan RJ, Alvarez RD, Armstrong DK, et al. Ovarian cancer, version 3.2012. J Natl Compr Canc Netw 2012;10:1339-49
12. Cristea M, Han E, Salmon L, Morgan RJ. Practical considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol 2010;2:175-87
13. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43
14. Marth C, Walker JL, Barakat RR, et al. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer 2007;109:645-9
15. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96
16. Burger RA, Brady MF, Bookman MA, et al. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83
17. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent for recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 2007;25:5165-71
18. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-45
19. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(Suppl): Abstract LBA5002
20. Leone Roberti Maggiore U, Bellati F, Ruscito I, et al
21. Banerjee S, Kaye SB. New Strategies in the treatment of ovarian cancer - current clinical perspectives and future potential. Clin Cancer Res 2013;19:961-8
22. Suh DH, Kim JW, Kim K, et al. Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol 2013;24:66-82
23. Ng R, Chen EX. Sorafenib (BAY 43-9006): Review of clinical development. Clin Pharmacol 2006;1:223-8
24. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
25. Caraglia M, Tassone P, Marra M, et al. Targeting Raf-kinase: Molecular rationales and translational issues. Ann Oncol 2006;17(Suppl 7):vii124-7
26. Chia WJ, Tang BL. Emerging roles for Rab family GTPases in human cancer. Biochim Biophys Acta 2009;1795:110-16
27. Williams NG, Roberts TM. Signal transduction pathways involving the Raf proto-oncogene. Cancer Metastasis Rev 1994;13:105-16
28. Rubinfeld H, Seger R. The ERK cascade: A prototype of MAPK signaling. Mol Biotechnol 2005;31:151-74
29. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25-40
30. Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 2011;30:3477-88
31. Ellis LM, Hicklin DJ. VEGF-targeted therapy: Mechanisms of antitumour activity. Nat Rev Cancer 2008;8:579-91
32. Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61
33. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74
34. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64
35. Uyttendaele H, Ho J, Rossant J, Kitajewski J. Vascular patterning defects associated with expression of activated notch4 in embryonic endothelium. Proc Natl Acad Sci USA 2001;98:5643-8
36. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72
37. Flaherty KT, Redlinger M, Schuchter LM, et al. Phase I/II, pharmacokinetic and pharmacodynamics trial of BAY 43-9006 alone in patients with metastatic melanoma. J Clin Oncol 2005;23:3037
38. Agency EM. Sorafenib (Nexavar): Summary of product characteristics (online). Available from: Http://wwwemeaeuropaeu/humandocs/PDFs/EPAR7nexavar/H- 690-Pi-enpdf17
39. Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-92
40. Rini BI. Sorafenib. Expert Opin Pharmacother 2006;7:453-61
41. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72
42. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-61
43. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-80
44. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-94
45. Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12:144-51
46. Mross K, Steinbild S, Baas F, et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 2007;43:55-63
47. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008;26:3709-14
48. Lee JM, Sarosy GA, Annunziata CM, et al. Combination therapy: Intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 2010;102:495-9
49. Ramasubbaiah R, Perkins SM, Schilder J, et al. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol 2011;123:499-504
50. Matei D, Sill MW, Lankes HA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A gynecologic oncology group trial. J Clin Oncol 2011;29:69-75
51. Polcher M, Eckhardt M, Coch C, et al. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 2010;66:203-7
52. Welch SA, Hirte HW, Elit L, et al. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer 2010;20:787-93
53. Kohn EC, Lee J, Annunziata CM, et al. A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naive epithelial ovarian cancer (EOC) patients. J Clin Oncol 2011;29(Suppl): Abstract 5019 ASCO
54. Bodnar L, Go'rnas M, Szczylik C. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study. Gynecol Oncol 2011;123:33-6
55. Herzog TJ, Scambia G, Kim BG, et al. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol 2013; [Epub ahead of print]
56. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011;61:183-203
57. Rosa DD, Clamp AR, Collinson F, Jayson GC. Antiangiogenic therapy for ovarian cancer. Curr Opin Oncol 2007;19:497-505
58. Dal Lago L, D'Hondt V, Awada A. Selected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumors. Oncologist 2008;13:845-58
59. Woo HY, Heo J. Sorafenib in liver cancer. Expert Opin Pharmacother 2012;13:1059-67
60. Mangana J, Levesque MP, Karpova MB, Dummer R. Sorafenib in melanoma. Expert Opin Investig Drugs 2012;21:557-68
61. Strumberg D. Sorafenib for the treatment of renal cancer. Expert Opin Pharmacother 2012;13:407-19
62. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30
63. Flaherty KT, Lee SJ, Zhao F, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 2013;31:373-9
64. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-42
65. Azad NS, Annunziata CM, Steinberg SM, et al. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer 2008;112:1726-32
66. Sugiyama T, Kumagai S, Hatayama S. Treatments of epithelial ovarian cancer by histologic subtype. Japanese. Gan To Kagaku Ryoho 2009;36:187-92
67. Rauh-Hain JA, Penson RT. Potential benefit of sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 2008;18:934-6
68. Matsumura N, Mandai M, Okamoto T, et al. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci 2010;101:2658-63
69. Rahman M, Nakayama K, Ishibashi T, et al. A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies. Int J Mol Sci 2013;14:6067-73
70. Takano M, Kikuchi Y, Kudoh K, et al. Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: A report of six cases. Int J Clin Oncol 2011;16:605-9
71. Takano M, Ikeda Y, Kudoh K, et al. Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin. J Obstet Gynaecol Res 2013;39:872-5 Available from: Http:/www.cinicaltrials. gov; (ID protocol number: NCT01196429)
72. Available from: Http:/www.cinicaltrials. gov; (ID protocol number: NCT01824615)
73. Available from: Http:/www.cinicaltrials. gov; (ID protocol number: NCT00390611)
74. Available from: Http://www.chemspider. com/Chemical-Structure.187440. html? rid=e1577ab8-ad52-4318-af98-0c999862d2a1 [Accessed 22 March 2013]